WallStSmart

Electrocore LLC (ECOR)vsGE HealthCare Technologies Inc. (GEHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 60017% more annual revenue ($20.98B vs $34.90M). GEHC leads profitability with a 9.1% profit margin vs -44.1%. GEHC earns a higher WallStSmart Score of 57/100 (C).

ECOR

Avoid

26

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 6.7Quality: 5.0
Piotroski: 3/9Altman Z: -14.92

GEHC

Buy

57

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 5.7Quality: 4.5
Piotroski: 2/9Altman Z: 1.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ECORUndervalued (+84.1%)

Margin of Safety

+84.1%

Fair Value

$34.25

Current Price

$8.72

$25.53 discount

UndervaluedFair: $34.25Overvalued

Intrinsic value data unavailable for GEHC.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ECOR2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
42.6%10/10

Revenue surging 42.6% year-over-year

Debt/EquityHealth
-1.6710/10

Conservative balance sheet, low leverage

GEHC2 strengths · Avg: 8.0/10
P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

Areas to Watch

ECOR4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$72.34M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-478.7%2/10

ROE of -478.7% — below average capital efficiency

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.844/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-30.9%2/10

Earnings declined 30.9%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ECOR

The strongest argument for ECOR centers on Revenue Growth, Debt/Equity. Revenue growth of 42.6% demonstrates continued momentum.

Bull Case : GEHC

The strongest argument for GEHC centers on P/E Ratio, Price/Book.

Bear Case : ECOR

The primary concerns for ECOR are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

ECOR profiles as a hypergrowth stock while GEHC is a value play — different risk/reward profiles.

ECOR carries more volatility with a beta of 0.87 — expect wider price swings.

ECOR is growing revenue faster at 42.6% — sustainability is the question.

GEHC generates stronger free cash flow (112M), providing more financial flexibility.

Bottom Line

GEHC scores higher overall (57/100 vs 26/100). ECOR offers better value entry with a 84.1% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Electrocore LLC

HEALTHCARE · MEDICAL DEVICES · USA

electroCore, Inc., a commercial-stage medical device company, is dedicated to the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is headquartered in Rockaway, New Jersey.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?